

Eleanor Rigby

(Format: Short email communication summary for chart)

To: Patient Chart (Rigby, Eleanor DOB 05 Jan 1949, MRN SYN034)

From: Benjamin Carter, MD

Date: August 22, 2023

Subject: Routine Follow-up Call - Stable on Alectinib

Summary: Spoke with Ms. Rigby today for her routine 3-month telehealth check-in. She continues on Alectinib 600mg BID for ALK-positive Stage IV lung adenocarcinoma (diagnosed Feb 2021, started Alectinib Feb 25, 2021).

Status: Patient reports feeling excellent. No symptoms related to lung cancer or treatment. Remains active (gardening, community activities). No cough, dyspnea, bone pain (initial mets site). Denies myalgias, significant edema, constipation, visual changes, or other common Alectinib side effects. Adherence is perfect.

Pertinent History: ALK fusion positive, PD-L1 TPS 55% / CPS 60 / IC 2/+ (reflex tested). Known bone mets at diagnosis (T-spine, pelvis). On Alectinib x ~30 months with sustained response.

Plan:

- Continue Alectinib 600mg BID.
- Labs (CBC, CMP) ordered at local lab for completion this week. Will review results.
- Next surveillance CT C/A/P scheduled for mid-October 2023 (~3 months).
- Continue Brain MRI surveillance q6 months (last was June 2023 - stable/neg).
- Follow-up telehealth visit scheduled in 3 months after scans. Patient knows to call sooner with any concerns.

Impression: Excellent ongoing response and tolerability to long-term Alectinib therapy.

(End of Communication Summary)
